Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;111(1):104-108.
doi: 10.5935/abc.20180133.

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk

[Article in English, Portuguese]
Paulo Eduardo Ballvé Behr  1 , Emilio Hideyuki Moriguchi  2   3 , Iran Castro  4 , Luiz Carlos Bodanese  1 , Oscar Pereira Dutra  4 , Paulo Ernesto Leães  5 , Pedro Pimentel Filho  6
Affiliations
Review

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk

[Article in English, Portuguese]
Paulo Eduardo Ballvé Behr et al. Arq Bras Cardiol. 2018 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

Paulo Eduardo Ballvé Behr, MD, received lecture fees in continuing medical education programs from Amgen.

Emilio Hideyuki Moriguchi received lecture fees in continuing medical education programs from Amgen and Sanofi.

Luiz Carlos Bodanese, MD, participated as an investigator for the Odyssey and Rourier studies.

Oscar Pereira Dutra, MD, participated as an investigator for the Rourier study.

Paulo Ernesto Leães, MD, participated as an investigator for the Odyssey and Rourier studies.

Pedro Pimentel Filho, MD, participated as an investigator for the Odyssey and Rourier studies.

Figures

Figure 1
Figure 1
Absolute risk reduction for the same relative LDL-C level reduction from different initial LDL-C levels. (Reprint with permission from Oxford University Press).
See this image and copyright information in PMC

References

    1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. - PubMed
    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. - PMC - PubMed
    1. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578–2589. - PMC - PubMed
    1. Ridker PM, Mora S, Rose L, JUPITER Trial Study Group Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373–1379. - PMC - PubMed
    1. Kathiresan S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J Am Coll Cardiol. 2015;65(15):1562–1566. - PubMed

MeSH terms